Delaware
|
001-13988
|
36-3150143
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
500 West Monroe
|
|
|
Chicago,
|
|
60661
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Title of each class
|
|
Trading Symbol |
|
Name of each exchange on
which registered
|
Common Stock $0.01 Par Value
|
ATGE |
New York Stock Exchange
|
||
Common Stock $0.01 Par Value
|
ATGE
|
|
Item 1.01
|
Entry into a Material Definitive Agreement
|
Item 2.03 |
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. |
Item 7.01 |
Regulation FD Disclosure |
Item 9.01 |
Financial Statements and Exhibits |
|
ADTALEM GLOBAL EDUCATION INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Robert J. Phelan
|
|
|
|
Robert J. Phelan
|
|
|
|
Senior Vice President and Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
|
|
|
|
|
|
![]() |
MORGAN STANLEY & CO. LLC
1585 BROADWAY NEW YORK, NY 10036-8293 (212) 761-4000 |
Trade Date: |
As specified in Schedule I
|
Buyer: |
Issuer
|
Seller: |
MSCO
|
Shares: |
Common Stock, par value USD 0.01 per share, of Issuer (Ticker: ATGE)
|
Forward Price: |
A price equal to (i) the arithmetic mean (not a weighted average, subject to “Market Disruption Event” below) of the 10b-18 VWAP on each Calculation Date during the
Calculation Period minus (ii) the Discount.
|
Discount: |
As specified in Schedule I
|
10b-18 VWAP: |
On any Calculation Date, a price per Share equal to the volume-weighted average price of the Rule 10b-18 eligible trades in the Shares for the entirety of such
Calculation Date as determined by the Calculation Agent at 4:15 EST on such Calculation Date by reference to the screen entitled “ATGE <Equity> AQR SEC” or any successor page as reported by Bloomberg L.P. or any successor (without
regard to pre-open or after-hours trading outside of any regular trading session for such Calculation Date or block trades (as defined in Rule 10b-18(b)(5) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) on such Calculation Date), or, if the price displayed on such screen is clearly erroneous, as determined on a volume-weighted average basis by the
Calculation Agent in good faith and in a commercially reasonable manner.
|
Calculation Period: |
The period from, and including, the Calculation Period Start Date to, and including, the relevant Valuation Date.
|
Calculation Period Start Date: |
As specified in Schedule I
|
Calculation Dates: |
As specified in Schedule I
|
Initial Shares: |
As specified in Schedule I
|
Initial Share Delivery Date: |
As specified in Schedule I. On the Initial Share Delivery Date, Seller shall deliver to Buyer a number of Shares equal to the Initial Shares in accordance with Section
9.4 of the Equity Definitions, with the Initial Share Delivery Date being deemed to be a “Settlement Date” for purposes of such Section 9.4.
|
Prepayment: |
Applicable
|
Prepayment Amount: |
As specified in Schedule I
|
Prepayment Date: |
As specified in Schedule I
|
Exchange: |
New York Stock Exchange
|
Related Exchange: |
All Exchanges
|
Market Disruption Event: |
The definition of “Market Disruption Event” in Section 6.3(a) of the Equity Definitions is hereby amended by deleting the words “at any time during the one hour period
that ends at the relevant Valuation Time, Latest Exercise Time, Knock-in Valuation Time or Knock-out Valuation Time, as the case may be,” starting in the third line thereof.
|
Valuation Date(s): |
The earlier of (i) the Scheduled Valuation Date and (ii) any earlier accelerated Valuation Date as a result of MSCO’s election in accordance with the immediately
succeeding paragraph.
|
Scheduled Valuation Date: |
As specified in Schedule I, subject to postponement in accordance with “Market Disruption Event” above.
|
Lock-Out Date: |
As specified in Schedule I
|
Physical Settlement: |
Applicable. On any Valuation Date (including any Acceleration Date, if applicable), the Calculation Agent shall calculate the Settlement Amount for the relevant
portion of the Transaction. The “Settlement Amount” for the Transaction is a number of Shares equal to (a) (i) the Prepayment Amount divided by (ii) the Forward Price minus
(b) the Initial Shares, rounded to the nearest whole number of Shares.
|
Settlement Currency: |
USD
|
Settlement Date: |
The date that falls one Settlement Cycle after the relevant Valuation Date or Acceleration Date if prior to the Scheduled Valuation Date for the relevant portion of the
Transaction (the final Settlement Date, the “Final Settlement Date”).
|
Buyer Settlement: |
If the Settlement Amount is negative, Buyer may elect that the Buyer Share Settlement provisions apply in lieu of the Buyer Cash Settlement Method provisions by written
notice to Seller, which notice shall be effective if received by Seller by the earlier of (i) the Scheduled Valuation Date and (ii) the Scheduled Trading Day immediately following the final Acceleration Date (such date, the “Buyer Election Date”).
|
Buyer Cash Settlement: |
If Cash Settlement is applicable, then Buyer shall pay to Seller the absolute value of the Buyer Cash Settlement Amount on the Buyer Cash Settlement Payment Date.
|
Buyer Cash Settlement Amount: |
An amount equal to (a) the aggregate of each negative Settlement Amount, multiplied by (b) the Buyer Settlement Price.
|
Buyer Settlement Price: |
Subject to “Market Disruption Event” above, an amount equal to the arithmetic mean of the 10b-18 VWAP for each Scheduled Trading Day in the Buyer Settlement Valuation
Period.
|
Buyer Settlement Valuation Period: |
A number of Scheduled Trading Days determined in good faith by the Calculation Agent in its commercially reasonable discretion to be necessary for MSCO to unwind its
commercially reasonable Hedge Position in a commercially reasonable manner using commercially reasonable efforts, beginning on the Scheduled Trading Day immediately following the Buyer Election Date, subject to “Market Disruption Event”
above.
|
Buyer Cash Settlement Payment Date: |
The Currency Business Day immediately following the last day of the Buyer Settlement Valuation Period.
|
Buyer Share Settlement: |
On the Final Settlement Date, Buyer shall deliver to Seller a number of Shares equal to the Buyer Share Settlement Percentage multiplied by the absolute value of the aggregate of each negative Settlement Amount. Buyer’s obligation under this provision shall be netted against any
obligations of Seller under “Physical Settlement” above on the Final Settlement Date.
|
Buyer Share Settlement Percentage: |
As specified in Schedule I
|
Other Applicable Provisions: |
The last sentence of Section 9.2, Sections 9.8, 9.9, 9.10 and 9.11 (except that the Representation and Agreement contained in Section 9.11 of the Equity Definitions
shall be modified by excluding any representations therein relating to restrictions, obligations, limitations or requirements under applicable securities laws arising as a result of the fact that Buyer is the issuer of the Shares) and Section
9.12 of the Equity Definitions will be applicable to the Transaction.
|
Potential Adjustment Event: |
In addition to the events described in Section 11.2(e) of the Equity Definitions, the occurrence of a Disrupted Day (including due to the occurrence of a Regulatory
Disruption) shall constitute a Potential Adjustment Event. In the case of any event described in the preceding sentence, the Calculation Agent may, in its commercially reasonable judgment, adjust any relevant terms of the Transaction as the
Calculation Agent determines appropriate to account for the economic effect on the Transaction of such event.
|
Different Dividend: |
For any calendar quarter, any dividend or distribution on the Shares with an ex-dividend date occurring during such calendar quarter (other than any dividend or
distribution of the type described in Section 11.2(e)(i) or Section 11.2(e)(ii)(A) of the Equity Definitions) (a “Dividend”) the amount or
value of which (as determined by the Calculation Agent), when aggregated with the amount or value (as determined by the Calculation Agent) of any and all previous Dividends with ex-dividend dates occurring in the same calendar quarter,
differs from the Ordinary Dividend Amount.
|
Ordinary Dividend Amount: |
As specified in Schedule I
|
Extraordinary Dividend: |
The per Share cash dividend or distribution, or a portion thereof, declared by Issuer on the Shares that is classified by the board of directors of Issuer as an
“extraordinary” dividend.
|
Consequences of Different Dividend: |
The declaration by the Issuer of any Different Dividend, the ex-dividend date for which occurs or is scheduled to occur during the Relevant Dividend Period (as defined
below) for the Transaction, shall constitute an Additional Termination Event in respect of such Transaction, with Buyer as the sole Affected Party and such Transaction as the sole Affected Transaction.
|
Early/Late Ordinary Dividend Payment: |
If an ex-dividend date for any Dividend that is neither (x) a dividend or distribution of the type described in Section 11.2(e)(i) or Section 11.2(e)(ii)(A) of the
Equity Definitions nor (y) an Extraordinary Dividend, occurs during any calendar quarter occurring (in whole or in part) during the Relevant Dividend Period and such ex-dividend date is not on the Scheduled Ex-Dividend Date for such calendar
quarter, the Calculation Agent shall in a good faith and in a commercially reasonable manner make such adjustment to the exercise, settlement, payment or any other terms of the Transaction as the Calculation Agent determines appropriate to
account solely for the economic effect of the timing of such Dividend on the Transaction.
|
Scheduled Ex-Dividend Dates: |
As specified in Schedule I
|
Relevant Dividend Period: |
The period from, and including, the Trade Date for the Transaction to, and including, the later of (i) the fifth Scheduled Trading Day following the final Valuation
Date for the Transaction and (ii) the last day of any Buyer Settlement Valuation Period for the Transaction.
|
Method of Adjustment: |
Calculation Agent Adjustment
|
Share-for-Share: |
Modified Calculation Agent Adjustment
|
Share-for-Other: |
Cancellation and Payment
|
Share-for-Combined: |
Component Adjustment
|
Tender Offer: |
Applicable
|
Share-for-Share: |
Modified Calculation Agent Adjustment
|
Share-for-Other: |
Modified Calculation Agent Adjustment
|
Share-for-Combined: |
Modified Calculation Agent Adjustment
|
New Shares: |
In the definition of New Shares in Section 12.1(i) of the Equity Definitions, the text in clause (i) thereof shall be deleted in its entirety and replaced with
“publicly quoted, traded or listed on any of the New York Stock Exchange, The NASDAQ Global Select Market or The NASDAQ Global Market (or their respective successors)”.
|
Composition of Combined Consideration: |
Not Applicable
|
Nationalization, Insolvency or Delisting: |
Cancellation and Payment; provided that, in addition to the
provisions of Section 12.6(a)(iii) of the Equity Definitions, it shall constitute a Delisting if the Exchange is located in the United States and the Shares are not immediately re-listed, re-traded or re-quoted on any of the New York
Stock Exchange, The NASDAQ Global Select Market or The NASDAQ Global Market (or their respective successors); if the Shares are immediately re-listed, re-traded or re-quoted on any such exchange or quotation system, such exchange or
quotation system shall thereafter be deemed to be the Exchange.
|
Change in Law: |
Applicable; provided that Section 12.9(a)(ii) of the Equity
Definitions is hereby amended by (i) replacing the phrase “the interpretation” in the third line thereof with the phrase “, or announcement or statement of, the formal or informal interpretation”, (ii) replacing the word “Shares” where it
appears in clause (X) thereof with the words “Hedge Position” and (iii) adding the words “, or holding, acquiring or disposing of Shares or any Hedge Position relating to,” after the word “under” in clause (Y) thereof; provided further that (i) any
determination as to whether (A) the adoption of or any change in any applicable law or regulation (including, for the avoidance of doubt and without limitation, (x) any tax law or (y) adoption or promulgation of new regulations authorized or
mandated by existing statute) or (B) the promulgation of or any change in the interpretation by any court, tribunal or regulatory authority with competent jurisdiction of any applicable law or regulation (including any action taken by a
taxing authority), in each case, constitutes a “Change in Law” shall be made without regard to Section 739 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 or any similar legal certainty provision in any legislation
enacted, or rule or regulation promulgated, on or after the Trade Date, and (ii) Section 12.9(a)(ii) of the Equity Definitions is hereby amended by replacing the parenthetical beginning after the word “regulation” in the second line thereof
the words “(including, for the avoidance of doubt and without limitation, (x) any tax law or (y) adoption or promulgation of new regulations authorized or mandated by existing statute)”.
|
Failure to Deliver: |
Applicable
|
Insolvency Filing: |
Applicable
|
Hedging Disruption: |
Applicable
|
Increased Cost of Hedging: |
Applicable
|
Loss of Stock Borrow: |
Applicable
|
Maximum Stock Loan Rate: |
As specified in Schedule I
|
Increased Cost of Stock Borrow: |
Applicable
|
Initial Stock Loan Rate: |
As specified in Schedule I
|
Determining Party: |
For all applicable events, MSCO
|
Hedging Party: |
For all applicable events, MSCO
|
Non-Reliance: |
Applicable
|
Agreements and Acknowledgments
Regarding Hedging Activities:
|
Applicable
|
Additional Acknowledgments: |
Applicable
|
Hedging Adjustments: |
Whenever the Calculation Agent is called upon to make a determination, calculation or adjustment pursuant to the terms of this Confirmation or the Equity Definitions to
take into account the effect of an event, the Calculation Agent shall make such determination, calculation or adjustment by reference to the effect of such event on MSCO with the Calculation Agent assuming that MSCO maintains a commercially
reasonable Hedge Position in respect of the Transaction.
|
3. |
Calculation Agent: |
MSCO
|
4. |
Account Details and Notices: |
(a)
|
Account for delivery of Shares to Issuer:
To be provided by Issuer.
|
(c)
|
Account for payments and delivery of Shares to MSCO:
|
(d)
|
For purposes of this Confirmation:
|
(i)
|
Address for notices or communications to Issuer:
|
(ii)
|
Address for notices or communications to MSCO:
|
(a)
|
Section 11.2(a) of the Equity Definitions is hereby amended by deleting the words “a diluting or
concentrative effect on the theoretical value of the relevant Shares” and replacing them with the words “an economic effect on the Shares or the relevant Transaction; provided that such event is not based on (a) an observable market, other
than the market for Issuer’s own stock, or (b) an observable index, other than an index calculated and measured solely by reference to Issuer’s own operations.”
|
(b)
|
The first sentence of Section 11.2(c) of the Equity Definitions, prior to clause (A) thereof, is hereby
amended to read as follows: ‘(c) If “Calculation Agent Adjustment” is specified as the Method of Adjustment in the related Confirmation of a Share Option Transaction or Share Forward Transaction, then, following the announcement or
occurrence of any Potential Adjustment Event, the Calculation Agent will determine whether such Potential Adjustment Event has an economic effect on the Transaction and, if so, will in its good faith and commercially reasonable discretion
(i) make appropriate adjustment(s), if any, to any one or more of:’ and the portion of such sentence immediately preceding clause (ii) thereof is hereby amended by deleting the words “diluting or concentrative” and the words “(provided that
no adjustments will be made to account solely for changes in volatility, expected dividends, stock loan rate or liquidity relative to the relevant Share)” and replacing such latter phrase with the words “(including adjustments to account
for changes in volatility, stock loan rate or liquidity relevant to the Shares or to the Transaction)”.
|
(c)
|
Section 11.2(e)(vii) of the Equity Definitions is hereby amended by deleting the words “diluting or
concentrative effect on the theoretical value of the relevant Shares” and replacing them with the words “economic effect on the Shares or the relevant Transaction”.
|
(d)
|
the definition of “Announcement Date” in Section 12.1(l) of the Equity Definitions is hereby amended by
(a) replacing the words “a firm” with the word “any” in the fourth lines thereof, (b) replacing the word “leads to the” with the words “, if completed, would lead to a” in the fifth line thereof, (c) replacing the words “voting shares” with
the word “, voting power or Shares” in the fifth line thereof, (d) inserting the words “by any entity” after the word “announcement” in the fourth line thereof and (e) inserting the words “or to explore the possibility of purchasing or
otherwise obtaining” after the word “obtain” in the fourth line thereof;
|
(e)
|
Section 12.3(d) of the Equity Definitions shall each be amended by replacing each occurrence of the words
“Tender Offer Date” by “Announcement Date.”
|
(f)
|
Section 12.6(c)(ii) of the Equity Definitions is hereby amended by replacing the words “the Transaction
will be cancelled,” in the first line with the words “MSCO will have the right to cancel the Transaction,”.
|
(g)
|
Section 12.9(b)(iv) of the Equity Definitions is hereby amended by (A) deleting (1) subsection (A) in its
entirety, (2) the phrase “or (B)” following subsection (A) and (3) the phrase “in each case” in subsection (B); and (B) replacing the phrase “neither the Non-Hedging Party nor the Lending Party lends Shares” with the phrase “such Lending
Party does not lend Shares” in the penultimate sentence.
|
(h)
|
Section 12.9(b)(v) of the Equity Definitions is hereby amended by (A) adding the word “or” immediately
before subsection “(B)” and deleting the comma at the end of subsection (A); and (B)(1) deleting subsection (C) in its entirety, (2) deleting the word “or” immediately preceding subsection (C) and (3) replacing in the penultimate sentence
the words “either party” with “the Hedging Party” and (4) deleting clause (X) in the final sentence.
|
(a)
|
If an Acquisition Transaction Announcement occurs on or prior to the final Valuation Date, then the Calculation Agent shall
in its good faith and commercially reasonable discretion make such adjustments to the exercise, settlement, payment or any other terms of the Transaction as the Calculation Agent determines appropriate (including, without limitation and for
the avoidance of doubt, adjustments that would allow the Settlement Amount to be less than zero), at such time or at multiple times as the Calculation Agent determines appropriate, to account for the economic effect on the Transaction of
such event (including adjustments to account for changes in volatility, stock loan rate, value of any commercially reasonable Hedge Positions in connection with the Transaction, and liquidity relevant to the Shares or to such Transaction to
maintain a commercially reasonable hedge position). If an Acquisition Transaction Announcement occurs after the Trade Date but prior to the Lock-Out Date, the Lock-Out Date shall be deemed to be the date of such Acquisition Transaction
Announcement.
|
(b)
|
“Acquisition Transaction
Announcement” means (i) the announcement of an Acquisition Transaction, (ii) an announcement that Issuer or any of its subsidiaries has entered into an agreement, a letter of intent or an understanding designed to result in an
Acquisition Transaction, (iii) the announcement of the intention to solicit or enter into, or to explore strategic alternatives or other similar undertaking that may include, an Acquisition Transaction, (iv) any other announcement that in
the reasonable judgment of the Calculation Agent may result in an Acquisition Transaction or (v) any announcement subsequent to an Acquisition Transaction Announcement relating to an amendment, extension, withdrawal or other change to the
subject matter of a prior Acquisition Transaction Announcement. For the avoidance of doubt, the term “announcement” as used in the definition of Acquisition Transaction Announcement refers to any public statement and/or any announcement
related to an Acquisition Transaction, whether made by Issuer or a third party.
|
(c)
|
“Acquisition Transaction”
means (i) any Merger Event (for purposes of this definition, the definition of Merger Event shall be read with the references therein to “100%” being replaced by “15%” and to “50%” by “75%” and without reference to the clause beginning
immediately following the definition of Reverse Merger therein to the end of such definition), Tender Offer or Merger Transaction (as defined below) or any other transaction involving the merger of Issuer with or into any third party, (ii)
the sale or transfer of all or substantially all of the assets or liabilities of Issuer, (iii) a recapitalization, reclassification, binding share exchange or other similar transaction, (iv) any acquisition, lease, exchange, transfer,
disposition (including by way of spin-off or distribution) of assets or liabilities (including any capital stock or other ownership interests in subsidiaries) or other similar event by Issuer or any of its subsidiaries where the aggregate
consideration transferable or receivable by or to Issuer or its subsidiaries exceeds 15% of the market capitalization of Issuer and (v) any transaction with respect to which Issuer or its board of directors has a legal obligation to make a
recommendation to its shareholders in respect of such transaction (whether pursuant to Rule 14e-2 under the Exchange Act or otherwise).
|
(a)
|
Until the end of the Potential Purchase Period (as defined below), neither it nor any of its affiliated purchasers (as
defined in Rule 10b-18 under the Exchange Act, “Rule 10b-18”) shall directly or indirectly (which shall be deemed to include the writing
or purchase of any cash-settled or other derivative transaction which references Shares or structured Share repurchase or other derivative with a hedging period, calculation period or settlement valuation period or similar period that
overlaps with the Transaction) purchase, offer to purchase, place any bid or limit order relating to a purchase of or commence any tender offer relating to Shares (or any security convertible into or exchangeable for Shares) without the
prior written approval of MSCO or take any other action that would cause the purchase by MSCO of any Shares in connection with this Confirmation not to qualify for the safe harbor provided in Rule 10b-18 under the Exchange Act (assuming for
the purposes of this paragraph that such safe harbor were otherwise available for such purchases). “Potential Purchase Period” means the
period from, and including, the Trade Date to, and including, the latest of (i) the last day of any Buyer Settlement Valuation Period, (ii) the earlier of (A) the date five Exchange Business Days immediately following the last day of the
Calculation Period and (B) the Scheduled Valuation Date and (iii) if an Early Termination Date occurs or the Transaction is cancelled pursuant to Article 12 of the Equity Definitions, a date determined by MSCO in its commercially reasonable
discretion and communicated to Issuer no later than the Exchange Business Day immediately following such date (or, in the absence of such communication, the date that is five Exchange Business Days immediately following such date).
|
(b)
|
It will comply with all laws, rules and regulations applicable to it (including, without limitation, the Securities Act of
1933 (the “Securities Act”) and the Exchange Act) in connection with the transactions contemplated by this Confirmation.
|
(c)
|
Without limiting the generality of Section 13.1 of the Equity Definitions, it is not relying, and has not relied, upon MSCO
or any of its representatives or advisors with respect to the legal, accounting, tax or other implications of this Confirmation and that it has conducted its own analyses of the legal, accounting, tax and other implications of this
Confirmation, and that MSCO and its affiliates may from time to time effect transactions for their own account or the account of customers and hold positions in securities or options on securities of Issuer and that MSCO and its affiliates
may continue to conduct such transactions during the term of this Confirmation. Without limiting the generality of the foregoing, Issuer acknowledges that MSCO is not making any representations or warranties or taking any position or
expressing any view with respect to the treatment of the Transaction under any accounting standards including ASC Topic 260, Earnings Per Share, ASC Topic 815, Derivatives and Hedging, or ASC Topic 480, Distinguishing Liabilities from
Equity and ASC 815-40, Derivatives and Hedging – Contracts in Entity’s Own Equity (or any successor issue statements) or under FASB’s Liabilities & Equity Project.
|
(d)
|
Neither it nor any affiliates shall take any action that would cause a restricted period (as defined in Regulation M under
the Exchange Act (“Regulation M”)) to be applicable to any purchases of Shares, or of any security for which Shares is a reference
security (as defined in Regulation M), by Issuer or any affiliated purchasers (as defined in Regulation M) of Issuer during the Potential Purchase Period.
|
(e)
|
It will not during the term of the Transaction make, or, to the extent within its control, permit to be made, any public
announcement (as defined in Rule 165(f) under the Securities Act) of any Merger Transaction or potential Merger Transaction unless such public announcement is made prior to the open or after the close of the regular trading session on the
Exchange for the Shares. “Merger Transaction” means any merger, acquisition or similar transaction involving a recapitalization of
Issuer as contemplated by Rule 10b-18(a)(13)(iv) under the Exchange Act. Issuer acknowledges that any such public announcement may trigger the provision set forth in Section 8 above.
|
(f)
|
Not later than 7:00 AM New York City time on the day following the announcement of a Merger Transaction, Issuer shall
provide MSCO with written notice, which notice shall specify (i) the nature of such announcement; (ii) Issuer’s average daily “Rule 10b-18 purchases” as defined in Rule 10b-18 during the three full calendar months immediately preceding such
announcement and (iii) the number of Shares purchased pursuant to the block purchase proviso in Rule 10b-18(b)(4) under the Exchange Act for the three full calendar months preceding the date of such announcement. Such written notice shall
be deemed to be a certification by Issuer to MSCO that such information is true and correct. Issuer understands that MSCO will use this information in calculating the trading volume for purposes of Rule 10b-18. In addition, Issuer shall
promptly provide written notice to MSCO of the occurrence of the completion of such transaction or the completion of the vote by target shareholders related to such transaction. Issuer acknowledges that its delivery of such notices must
comply with the standards set forth in Section 10(c) below.
|
(g)
|
(A) Any Shares or Alternative Delivery Units delivered to MSCO may be transferred by and among MSCO and its affiliates and
Issuer shall effect such transfer without any further action by MSCO and (B) after the period of 6 months from the date that Issuer elects to deliver any Shares or Alternative Delivery Units pursuant to the terms of this Transaction (or no
later than 1 year from such date, if at the time of MSCO’s or its affiliate’s request, informational requirements of Rule 144 under the Securities Act are not satisfied with respect to Issuer) has elapsed in respect of any such election to
deliver Shares or Alternative Delivery Units to MSCO, Issuer shall promptly remove, or cause the transfer agent for such Shares or Alternative Delivery Units to remove, any legends referring to any restrictions or requirements related to
any applicable securities laws upon request by MSCO (or such affiliate of MSCO) to Issuer or such transfer agent, without any requirement for the delivery of any certificate, consent, agreement, opinion of counsel, notice or any other
document, any transfer tax stamps or payment of any other amount or any other action by MSCO (or such affiliate of MSCO). Notwithstanding anything to the contrary herein, to the extent the provisions of Rule 144 of the Securities Act or any
successor rule are amended, or the applicable interpretation thereof by the Securities and Exchange Commission or any court change after the Trade Date, the agreements of Issuer herein shall be deemed modified to the extent necessary, as
determined by MSCO, to comply with Rule 144 of the Securities Act, as in effect at the time of delivery of the relevant Shares or Alternative Delivery Units.
|
(a)
|
Issuer hereby represents and warrants to MSCO on the date hereof and on and as of the Initial Share Delivery Date that:
|
(i)
|
None of Issuer and its officers and directors is aware of any material nonpublic information regarding Issuer or the Shares,
and is entering into the Transaction in good faith and not as part of a plan or scheme to evade the prohibitions of federal securities laws, including, without limitation, Rule 10b-5 under the Exchange Act and (B) Issuer agrees not to alter
or deviate from the terms of this Confirmation or enter into or alter a corresponding or hedging transaction or position with respect to the Shares (including, without limitation, with respect to any securities convertible or exchangeable
into the Shares) during the term of this Confirmation. Without limiting the generality of the foregoing, all reports and other documents filed by Issuer with the Securities and Exchange Commission pursuant to the Exchange Act when
considered as a whole (with the more recent such reports and documents deemed to amend inconsistent statements contained in any earlier such reports and documents) do not contain any untrue statement of a material fact or any omission of a
material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances in which they were made, not misleading.
|
(ii)
|
The transactions contemplated by this Confirmation have been authorized under Issuer’s publicly announced program to
repurchase Shares prior to the Trade Date.
|
(iii)
|
Issuer is not entering into the Transaction or making any election hereunder to facilitate a distribution of the Shares (or
any security convertible into or exchangeable for Shares) or in connection with a future issuance of securities.
|
(iv)
|
Issuer is not entering into the Transaction or making any election hereunder to create actual or apparent trading activity
in the Shares (or any security convertible into or exchangeable for Shares) or to raise or depress the price of the Shares (or any security convertible into or exchangeable for Shares) in violation of the federal securities laws.
|
(v)
|
There have been no purchases of Shares in Rule 10b-18 purchases of blocks pursuant to the once-a-week block exception
contained in Rule 10b-18(b)(4) by or for Issuer or any of its affiliated purchasers during each of the four calendar weeks preceding the Trade Date and during the calendar week in which the Trade Date occurs (“Rule 10b-18 purchase”,
“blocks” and “affiliated purchaser” each as defined in Rule 10b-18).
|
(vi)
|
Issuer is as of the date hereof, the Prepayment Date, any Buyer Election Date and any Buyer Cash Settlement Payment Date,
and after giving effect to the transactions contemplated hereby will be, Solvent. As used in this paragraph, the term “Solvent” means,
with respect to a particular date, that on such date (A) the present fair market value (or present fair saleable value) of the assets of Issuer is not less than the total amount required to pay the liabilities of Issuer on its total
existing debts and liabilities (including contingent liabilities) as they become absolute and matured, (B) Issuer is able to realize upon its assets and pay its debts and other liabilities, contingent obligations and commitments as they
mature and become due in the normal course of business, (C) assuming consummation of the transactions as contemplated by this Confirmation, Issuer is not incurring debts or liabilities beyond its ability to pay as such debts and liabilities
mature, (D) Issuer is not engaged in any business or transaction, and does not propose to engage in any business or transaction, for which its property would constitute unreasonably small capital after giving due consideration to the
prevailing practice in the industry in which Issuer is engaged, (E) Issuer is not a defendant in any civil action that could reasonably be expected to result in a judgment that Issuer is or would become unable to satisfy, (F) Issuer is not
“insolvent” (as such term is defined under Section 101(32) of the U.S. Bankruptcy Code (Title 11 of the United States Code) (the “Bankruptcy
Code”)) and (G) Issuer would be able to purchase Shares with an aggregate purchase price equal to the Prepayment Amount in compliance with the corporate laws of the jurisdiction of its incorporation.
|
(vii)
|
Issuer is not, and after giving effect to the transactions contemplated hereby will not be, required to register as an
“investment company” as such term is defined in the Investment Company Act of 1940, as amended.
|
(viii)
|
No state or local (including non-U.S. jurisdictions) law, rule, regulation or regulatory order applicable to the Shares
would give rise to any reporting, consent, registration or other requirement (including without limitation a requirement to obtain prior approval from any person or entity) as a result of MSCO or its affiliates owning or holding (however
defined) Shares.
|
(ix)
|
Issuer (A) is capable of evaluating investment risks independently, both in general and with regard to all transactions and
investment strategies involving a security or securities; (B) will exercise independent judgment in evaluating the recommendations of any broker-dealer or its associated persons, unless it has otherwise notified the broker-dealer in
writing; and (C) has total assets of at least USD 50,000,000 as of the date hereof.
|
(x)
|
Issuer confirms that in connection with the negotiation, execution and performance of the Transaction MSCO has not acted and
will not act as structuring adviser, adviser or fiduciary and that the sole role of MSCO in connection with the Transaction is as a principal counterparty.
|
(b)
|
Issuer acknowledges and agrees that the Initial Shares may be sold short to Issuer. Issuer further acknowledges and agrees
that MSCO may purchase Shares in connection with the Transaction, which Shares may be used to cover all or a portion of such short sale or may be delivered to Issuer. Such purchases and any other market activity by MSCO will be conducted
independently of Issuer by MSCO as principal for its own account. All of the actions to be taken by MSCO in connection with the Transaction shall be taken by MSCO independently and without any advance or subsequent consultation with
Issuer.
|
(c)
|
It is the intent of the parties that the Transaction comply with the requirements of Rule 10b5-1(c)(1)(i)(B) of the Exchange
Act, and the parties agree that this Confirmation shall be interpreted to comply with the requirements of such rule, and Issuer shall not take any action that results in the Transaction not so complying with such requirements. Without
limiting the generality of the preceding sentence, Issuer acknowledges and agrees that (A) Issuer does not have, and shall not attempt to exercise, any influence over how, when or whether MSCO effects any market transactions in connection
with the Transaction and (B) neither Issuer nor its officers or employees shall, directly or indirectly, communicate any information regarding Issuer or the Shares to any employee of MSCO or its Affiliates, other than employees identified
by MSCO to Issuer in writing as employees not responsible for executing market transactions in connection with the Transaction. Issuer also acknowledges and agrees that any amendment, modification, waiver or termination of this
Confirmation must be effected in accordance with the requirements for the amendment or termination of a “plan” as defined in Rule 10b5-1(c) under the Exchange Act. Without limiting the generality of the foregoing, any such amendment,
modification, waiver or termination shall be made in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b-5 under the Exchange Act, and no such amendment, modification, waiver or termination shall be made at
any time at which Issuer or any officer or director of Issuer is aware of any material nonpublic information regarding Issuer or the Shares.
|
(d)
|
Each of Issuer and MSCO represents and warrants to the other that it is an “eligible contract participant” as defined in
Section 1a(18) of the U.S. Commodity Exchange Act, as amended.
|
(e)
|
Each of Issuer and MSCO acknowledges that the offer and sale of the Transaction to it is intended to be exempt from
registration under the Securities Act by virtue of Section 4(a)(2) thereof. Accordingly, it represents and warrants to the other party that (i) it has the financial ability to bear the economic risk of its investment in the Transaction and
is able to bear a total loss of its investment, (ii) it is an “accredited investor” as that term is defined in Regulation D under the Securities Act, (iii) it is entering into the Transaction for its own account and without a view to the
distribution or resale thereof and (iv) the assignment, transfer or other disposition of the Transaction has not been and will not be registered under the Securities Act and is restricted under this Confirmation, the Securities Act and
state securities laws.
|
(a)
|
During the period from (and including) the Trade Date to (and including) the Settlement Date, MSCO and its Affiliates may
buy or sell Shares or other securities or buy or sell options or futures contracts or enter into swaps or other derivative transactions in order to establish, maintain or adjust its Hedge Position with respect to the Transaction.
|
(b)
|
MSCO and its Affiliates also may be active in the market for the Shares or options, futures contracts, swaps or other
derivative transactions relating to the Shares other than in connection with hedging activities in relation to the Transaction.
|
(c)
|
MSCO shall make its own determination as to whether, when and in what manner any hedging or market activities in Issuer’s
securities or other securities or transactions shall be conducted and shall do so in a manner that it deems appropriate to hedge its price and market risk with respect to the Transaction.
|
(d)
|
Any such market activities of MSCO and its Affiliates may affect the market price and volatility of the Shares, including
the 10b-18 VWAP, the Forward Price, and the Buyer Settlement Price, each in a manner that may be adverse to Issuer.
|
(a)
|
Issuer agrees and acknowledges that MSCO is a “financial institution,” “financial participant” and “swap participant” within
the meaning of Sections 101(22), 101(22A) and 101(53C) of the Bankruptcy Code. The parties hereto further agree and acknowledge that it is the intent of the parties that (A) this Confirmation is a “securities contract,” as such term is
defined in Section 741(7) of the Bankruptcy Code, with respect to which each payment and delivery hereunder or in connection herewith is a “termination value,” “payment amount,” “offset or net out” or “other transfer obligation” within the
meaning of Section 362(b) of the Bankruptcy Code and a “settlement payment,” within the meaning of Section 546(e) of the Bankruptcy Code, (B) this Confirmation is a “swap agreement,” as such term is defined in Section 101(53B) of the
Bankruptcy Code, with respect to which each payment and delivery hereunder or in connection herewith is a “transfer” within the meaning of Section 546(g) of the Bankruptcy Code, (C) the rights given to MSCO under this Confirmation and under
the Agreement upon the occurrence of an Event of Default with respect Issuer constitute “contractual rights” to cause the liquidation, termination or acceleration of or the offset or net out termination values under or in connection with a
“securities contract” and a “swap agreement”, (D) this Confirmation is a “master netting agreement’ as defined in 101(38A) of the Bankruptcy Code and (E)MSCO is entitled to the protections afforded by, among other sections, Sections
362(b)(6), 362(b)(17), 362(o), 546(e), 546(g), 548(d)(2), 555, 560, and 561 of the Bankruptcy Code and .
|
(b)
|
MSCO acknowledges and agrees that this Confirmation is not intended to convey to MSCO rights against Issuer with respect to
the Transaction that are senior to the claims of common stockholders of Issuer in any United States bankruptcy proceedings of Issuer; provided
that nothing herein shall limit or shall be deemed to limit MSCO’s right to pursue remedies in the event of a breach by Issuer of its obligations and agreements with respect to the Transaction; provided further that nothing herein shall limit or shall be deemed to limit MSCO’s rights in respect of any transactions other than this Transaction.
|
(c)
|
Notwithstanding any provision of this Confirmation or any other agreement between the parties to the contrary, neither the
obligations of Issuer nor the obligations of MSCO hereunder are secured by any collateral, security interest, pledge or lien.
|
(d)
|
Each party waives any and all rights it may have to set off obligations arising under the Agreement and the Transaction
against other obligations between the parties, whether arising under any other agreement, applicable law or otherwise.
|
(e)
|
Notwithstanding anything to the contrary herein, MSCO may, by prior notice to Issuer, satisfy its obligation to deliver any
Shares or other securities on any date due (an “Original Delivery Date”) by making separate deliveries of Shares or such securities, as
the case may be, at more than one time on or prior to such Original Delivery Date, so long as the aggregate number of Shares and other securities so delivered on or prior to such Original Delivery Date is equal to the number required to be
delivered on such Original Delivery Date. Any Shares delivered pursuant to this provision shall be included in the calculation of the Settlement Amount.
|
(f)
|
It shall constitute an Additional Termination Event with respect to which the Transaction is the sole Affected Transaction
and Issuer is the sole Affected Party if, at any time on or prior to the final Valuation Date, the price per Share on the Exchange, as determined by the Calculation Agent, is at or below the Threshold Price (as specified in Schedule I).
|
ADTALEM GLOBAL EDUCATION INC.
|
MORGAN STANLEY & CO. LLC
|
By: /s/ Robert J. Phelan
|
By: /s/ Darren McCarley
|
Name: Robert J. Phelan
|
Name: Darren McCarley
|
Title: Senior Vice President, Chief Financial Officer
|
Title: Managing Director
|
CHICAGO--(BUSINESS WIRE)--March 14, 2022--Adtalem Global Education, Inc. (NYSE: ATGE), a leading healthcare educator, today announced that it has commenced an offer to purchase for cash (the “Asset Sale Offer”) up to $373,333,000 of its 5.500% Senior Notes due 2028 (the “Notes”), with a portion of the net cash proceeds received from its previously announced divestiture of the financial services segment. The Asset Sale Offer is being made pursuant to the indenture governing the Notes (as amended and supplemented, the “Indenture”) and an Offer to Purchase, dated March 14, 2022 and related Letter of Transmittal, which more fully set forth the terms and conditions of the Asset Sale Offer.
The Asset Sale Offer will expire at 5:00 P.M., New York City time, on April 8, 2022, unless extended or earlier terminated. Under the terms of the Asset Sale Offer, holders of the Notes who validly tender and do not withdraw their Notes prior to 5:00 P.M., New York City time, on April 8, 2022 (as such time and date may be extended) and whose Notes are accepted for purchase, will receive the applicable “Purchase Price,” which equals 100% of the principal amount of the Notes, equivalent to $1,000 per $1,000 principal amount of Notes, plus accrued and unpaid interest and additional interest, if any, up to, but not including, the date of payment. As provided in the Indenture, if at the Expiration Date the Notes tendered exceeds $373,333,000, Adtalem will purchase Notes on a pro rata basis to the extent practicable, by lot or by other such method as the trustee shall deem fair and appropriate. In the event that less than $373,333,000 in principal amount of Notes is tendered in the Asset Sale Offer, all of the tendered Notes will be repurchased by Adtalem.
5.500% Senior Notes due 2028
Title of Security |
CUSIP Number |
Principal Amount Outstanding |
Purchase Price(1) |
|||
5.500% Senior Notes due 2028 |
|
00737W AA7 (144A) |
|
$800,000,000 |
|
$1,000.00 plus accrued and unpaid interest and additional interest, if any, up to, but not including, the purchase date |
________________ |
|
(1) |
Per $1,000.00 principal amount of Notes validly tendered and accepted for purchase. As provided in the Indenture, if at the Expiration Date the Notes tendered exceeds $373,333,000, Adtalem will purchase Notes on a pro rata basis to the extent practicable, by lot or by other such method as the trustee shall deem fair and appropriate. In the event that less than $373,333,000 in principal amount of Notes is tendered in the Asset Sale Offer, all of the tendered Notes will be repurchased by Adtalem. |
This press release does not constitute a notice of redemption under the optional redemption provisions of the Indenture, nor does it constitute an offer to sell, or a solicitation of an offer to buy, any security. No offer, solicitation, or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful.
Requests for documents relating to the Asset Sale Offer may be directed to U.S. Bank Trust Company, National Association, the Depositary and Paying Agent, at cts.specfinance@usbank.com.
About Adtalem Global Education
Adtalem Global Education (NYSE: ATGE) is a leading healthcare educator and provider of professional talent to the healthcare industry. With a dedicated focus on driving strong outcomes that increase workforce preparedness, Adtalem empowers a diverse learner population to achieve their goals and make inspiring contributions to their communities. Adtalem is the parent organization of American University of the Caribbean School of Medicine, Chamberlain University, Ross University School of Medicine, Ross University School of Veterinary Medicine and Walden University. Adtalem and its institutions have more than 10,000 employees and a network of more than 275,000 alumni. Adtalem was named one of America’s Most Responsible Companies 2021 by Newsweek, and one of America’s Best Employers for Diversity 2021 by Forbes. Follow Adtalem on Twitter @adtalemglobal, LinkedIn or visit Adtalem.com for more information.
Forward-Looking Statements
Certain statements contained in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, which includes statements regarding the future impacts of the COVID-19 pandemic, the efficacy and distribution of the vaccines, and the expected synergies from the recent Walden acquisition. Forward-looking statements can also be identified by words such as “future,” “believe,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “may,” “will,” “would,” “could,” “can,” “continue,” “preliminary,” “range,” and similar terms. These forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those described in the statements. These risk and uncertainties include the risk factors described in Item 1A. “Risk Factors” of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) and our other filings with the SEC. These forward-looking statements are based on information available to us as of the date any such statements are made, and we do not undertake any obligation to update any forward-looking statement, except as required by law.
Investor Contact
Chandrika Nigam
Chandrika.Nigam@Adtalem.com
312-681-3209
Media Contact
Kelly Finelli
Kelly.Finelli@adtalem.com
872-270-0230
CHICAGO--(BUSINESS WIRE)--March 15, 2022--Adtalem Global Education, Inc. (NYSE: ATGE), a leading healthcare educator, today entered an accelerated share repurchase (“ASR”) agreement with Morgan Stanley & Co. LLC (“Morgan Stanley”) to repurchase $150 million of the company’s common stock. In addition to the $150 million ASR program, the Adtalem board of directors also authorized open market share repurchases of up to $300 million of the company’s common stock over the next 36 months, both of which were previously announced on March 1, 2022.
“The accelerated share repurchase program and open market purchase authorization evidence our firm belief that the Adtalem equity is undervalued and our confidence in the long-term prospects of the company,” said Steve Beard, president and CEO of Adtalem Global Education. “We will begin to bridge the gap between the intrinsic value of our assets and the market capitalization of the company through this action and an ongoing commitment to improved operational performance.”
The company is funding the ASR with existing cash resources. Under the terms of the agreement, Adtalem will receive an initial share delivery of approximately 4.7 million shares, with the final settlement scheduled to occur no later than the second quarter of fiscal year 2023. The final number of shares to be repurchased by the company under the ASR will be based on the volume-weighted average stock price of Adtalem’s common stock during the term of the agreement, less a discount and subject to adjustments.
Morgan Stanley has acted in the sole capacity of principal counterparty to Adtalem in connection with the negotiation and execution of the ASR.
About Adtalem Global Education
Adtalem Global Education (NYSE: ATGE) is a leading healthcare educator and provider of professional talent to the healthcare industry. With a dedicated focus on driving strong outcomes that increase workforce preparedness, Adtalem empowers a diverse learner population to achieve their goals and make inspiring contributions to their communities. Adtalem is the parent organization of American University of the Caribbean School of Medicine, Chamberlain University, Ross University School of Medicine, Ross University School of Veterinary Medicine and Walden University. Adtalem and its institutions have more than 10,000 employees and a network of more than 275,000 alumni. Adtalem was named one of America’s Most Responsible Companies 2021 by Newsweek, and one of America’s Best Employers for Diversity 2021 by Forbes. Follow Adtalem on Twitter @adtalemglobal, LinkedIn or visit Adtalem.com for more information.
Forward-Looking Statements
Certain statements contained in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, which includes statements regarding the future impacts of the COVID-19 pandemic, the efficacy and distribution of the vaccines, and the expected synergies from the recent Walden acquisition. Forward-looking statements can also be identified by words such as “future,” “believe,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “may,” “will,” “would,” “could,” “can,” “continue,” “preliminary,” “range,” and similar terms. These forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those described in the statements. These risk and uncertainties include the risk factors described in Item 1A. “Risk Factors” of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) and our other filings with the SEC. These forward-looking statements are based on information available to us as of the date any such statements are made, and we do not undertake any obligation to update any forward-looking statement, except as required by law.
Investor Contact
Chandrika Nigam
Chandrika.Nigam@Adtalem.com
312-681-3209
Media Contact
Kelly Finelli
Kelly.Finelli@adtalem.com
872-270-0230